Zacks: Aptevo Therapeutics Inc (APVO) Given $11.50 Average Target Price by Brokerages
Aptevo Therapeutics Inc (NASDAQ:APVO) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus target price of $11.50 for the company and are anticipating that the company will post ($0.59) EPS for the current quarter, according to Zacks. Zacks has also assigned Aptevo Therapeutics an industry rank of 82 out of 255 based on the ratings given to related companies.
Several brokerages have recently commented on APVO. ValuEngine downgraded shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, June 29th. Zacks Investment Research downgraded shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $11.00 price objective on shares of Aptevo Therapeutics in a research report on Friday, August 10th.
Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.07. The firm had revenue of $6.83 million for the quarter, compared to the consensus estimate of $4.17 million. Aptevo Therapeutics had a net margin of 74.01% and a negative return on equity of 45.53%. Equities research analysts expect that Aptevo Therapeutics will post -2.41 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. EAM Investors LLC purchased a new position in Aptevo Therapeutics during the second quarter valued at $552,000. Renaissance Technologies LLC grew its stake in Aptevo Therapeutics by 53.3% during the second quarter. Renaissance Technologies LLC now owns 1,149,400 shares of the biotechnology company’s stock valued at $5,736,000 after acquiring an additional 399,400 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Aptevo Therapeutics by 11.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,219,852 shares of the biotechnology company’s stock valued at $3,989,000 after acquiring an additional 123,236 shares in the last quarter. Citadel Advisors LLC grew its stake in Aptevo Therapeutics by 215.4% during the first quarter. Citadel Advisors LLC now owns 39,653 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 27,079 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Aptevo Therapeutics by 346.6% during the first quarter. JPMorgan Chase & Co. now owns 254,282 shares of the biotechnology company’s stock valued at $832,000 after acquiring an additional 197,341 shares in the last quarter. 33.08% of the stock is owned by institutional investors.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Recommended Story: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.